Pulmatrix Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
1,201.00
835.00
335.00
153
Cost of Goods Sold (COGS) incl. D&A
-
2.00
-
-
-
-
Gross Income
-
2.00
-
-
-
-
SG&A Expense
523.00
3,116.00
24,219.00
17,917.00
17,564.00
20,253
EBIT
523.00
3,118.00
23,018.00
17,332.00
17,475.00
20,331
Unusual Expense
-
-
2,152.00
12,587.00
34.00
68
Non Operating Income/Expense
-
-
44.00
2.00
28.00
22
Interest Expense
-
-
953.00
881.00
643.00
186
Pretax Income
523.00
3,118.00
26,167.00
30,802.00
18,056.00
20,563
Income Tax
-
-
-
2,959.00
-
-
Consolidated Net Income
523.00
3,118.00
26,167.00
27,843.00
18,056.00
20,563
Net Income
523.00
3,118.00
26,167.00
27,843.00
18,056.00
20,563
Net Income After Extraordinaries
523.00
3,118.00
26,167.00
27,843.00
18,056.00
20,563
Net Income Available to Common
523.00
3,118.00
26,167.00
27,843.00
18,056.00
20,563
EPS (Basic)
0.28
3.82
3.23
1.88
0.93
4.98
Basic Shares Outstanding
1,860.00
814.50
8,089.90
14,815.20
19,371.60
4,126.40
EPS (Diluted)
0.28
3.83
3.23
1.88
0.93
4.98
Diluted Shares Outstanding
1,860.00
814.50
8,089.90
14,815.20
19,371.60
4,126.40
EBITDA
523.00
3,116.00
22,786.00
17,082.00
17,229.00
20,100

About Pulmatrix

View Profile
Address
99 Hayden Avenue
Lexington Massachusetts 02421
United States
Employees -
Website http://www.pulmatrix.com
Updated 07/08/2019
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The company focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.